Literature DB >> 2895665

Use of vecuronium and doxapram in patients susceptible to malignant hyperthermia.

H Ording1, L Fonsmark.   

Abstract

Neuromuscular blockade was obtained with vecuronium 108 micrograms kg-1 in 44 patients undergoing diagnostic muscle biopsy as part of an investigation of malignant hyperthermia (MH) susceptibility. At the termination of anaesthesia doxapram 1.43 mg kg-1 was given in an attempt to antagonize postoperative respiratory depression. Rectal, muscle and skin temperatures, blood lactate concentration and venous PCO2 were measured before, during and after anaesthesia. Susceptibility to MH was established by in vitro contracture tests according to the protocol of the European MH Group. Twenty patients were susceptible to MH (MHS), 19 were MH non-susceptible (MHN) and five MH equivocal (MHE). No adverse effects of the drugs were observed. There were no differences between the three groups in rectal or muscle temperature, blood lactate concentration or venous PCO2 at any time. Doxapram did not prevent an increase in postoperative PCO2. It is concluded that vecuronium and doxapram may be safely administered to patients susceptible to MH.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2895665     DOI: 10.1093/bja/60.4.445

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  2 in total

1.  Incidence of malignant hyperthermia reactions in 2,214 patients undergoing muscle biopsy.

Authors:  A S Carr; J Lerman; M Cunliffe; M E McLeod; B A Britt
Journal:  Can J Anaesth       Date:  1995-04       Impact factor: 5.063

2.  Postoperative malignant hyperthermia confirmed by calcium-induced calcium release rate after breast cancer surgery, in which prompt recognition and immediate dantrolene administration were life-saving: a case report.

Authors:  Natsumi Miyazaki; Takayuki Kobayashi; Takako Komiya; Toshio Okada; Yusuke Ishida; Hidekimi Fukui; Yukihiko Ogihara; Hiroyuki Uchino
Journal:  J Med Case Rep       Date:  2021-04-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.